The extension brings the Oxford, UK-based company’s round to $25.4 million (£18.8 million) in total, adding to the initial funding secured in March 2025.
Existing investors Parkwalk Advisors and Hostplus via the IP Group Hostplus Innovation Fund led the extension. New U.S.-based investor, Modi Ventures, also participated.
Brainomix said that, with existing operations in the U.S. (based in Chicago) and a portfolio of FDA-cleared solutions, its additional capital will enable the company to expand in the U.S. as it advances deployment of its Brainomix 360 Stroke and e-Lung AI-powered imaging platforms across multiple hospitals.
Powered by state-of-the-art AI algorithms, 360 Stroke provides real-time interpretations of brain scans. It aids in the treatment and transfer decisions for stroke patients, according to the company. The technology picked up expanded FDA clearance for the technology in April 2025. That came just months after the company partnered with Medtronic to integrate AI solutions into clinical practice.
The company says its platform represents the only stroke AI imaging tool with a demonstrated impact on treatment rates. A real-world evaluation of the system saw an association with a more than 50% increase in mechanical thrombectomy rates. The company initially won an FDA nod for its stroke imaging platform in 2023.
Brainomix e-Lung is an FDA-cleared, AI-powered imaging software platform that automatically identifies and quantifies features on CT lung scans. It aims to enable clinicians to more easily identify changes including subtle deteriorations over multiple scan timepoints.
“This investment reflects strong confidence in our technology, our team, and the impact Brainomix 360 Stroke and e-Lung can have on patient care,” said Dr. Michalis Papadakis, CEO and co-founder of Brainomix. “Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time, underscoring the need for hospital technologies that support clinicians at the point of care. With this investment extension, we are well-positioned to enhance customer support across the US and Europe, accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments.”
